You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Developing Software for Pharmacodynamics and Bioassay Studies

    SBC: TConneX Inc.            Topic: DHP16C001

    Thegoal is to develop asoftwaretool that implementsa novelapproach applicableto fitgeneral pharmacologic, toxicology, or other biomedical data, that mayexhibita non-monotonic dose-responserelationship for which thecurrent parametricmodels fail. Thesoftwareexplores dose-responserelationships using both monotonicand non-monotonicmodels,and estimates theassociated doseresponsecurves,which can further ...

    STTR Phase II 2019 Department of DefenseDefense Health Agency
  2. Principled Design of an Augmented Reality Trainer for Medics

    SBC: UNVEIL LLC            Topic: DHP17A003

    Augmented reality (AR) offers the ability to enhance existing combat medic training by including perceptual cues and adaptive training elements to traditional simulation-based training using manikins. Unveil has developed a training system called the Macrocognitive AR Trainer (MART). MART is designed to foster the development of macrocognitive skills (e.g., sensemaking, assessment skills, mental m ...

    STTR Phase II 2018 Department of DefenseDefense Health Agency
  3. Medical Device to Assess the Viability of Tissue Prior to Skin Grafting

    SBC: Spectral Md, Inc.            Topic: DHP17A006

    The primary objective of this Phase II proposal is to construct and validate the portable SpectralMD DeepView imaging technology designed previously in Phase I. This device allows surgeons to quickly and objectively assess tissue viability in burn surgery prior to skin grafting. DeepView uses machine learning and multispectral imaging to generate quantitative prognostic images with easily interpre ...

    STTR Phase II 2018 Department of DefenseDefense Health Agency
  4. Dynamic virtual moulage based on thin film adhesive displays

    SBC: ARCHIE MD INC.            Topic: DHA17A002

    Providing Army combat medics with meaningful experience in treatment of battlefield injuries is a particular challenge. Moulage has the potential to assist in acquiring what could otherwise be very hard-to-come-by preparatory experience for distressing real-life emergencies medics and soldiers may encounter in the field. However, current approaches to moulage are limited in their ability to reflec ...

    STTR Phase II 2018 Department of DefenseDefense Health Agency
  5. Infectious Disease Diagnostics and Differentiation of Viral vs. Bacterial Infections for Point ofCare Applications

    SBC: GENECAPTURE, INC.            Topic: CBD15C001

    GeneCapture, Inc. is proposing to develop a rapid in vitro diagnostic prototype using our patented molecular-based CAPTURE (ConfirmActive Pathogens Through Unamplified RNA Expression) assay. Based on the results and experience gained in our Phase I STTR contractHDTRA1-16C-0061: Infectious Disease Diagnostics and Differentiation of Viral vs. Bacterial Infections for Point of Care Applications, we p ...

    STTR Phase II 2018 Department of DefenseOffice for Chemical and Biological Defense
  6. POC Blood Coagulopathy Monitor

    SBC: CFD RESEARCH CORPORATION            Topic: DHA19A001

    Traumatic injuries account for 30% of all life years lost in the US and is the leading cause of death for people under 46 years of age. Uncontrolled bleeding or hemorrhage constitute 30-40% of trauma related deaths and are considered to be a major cause o

    STTR Phase I 2019 Department of DefenseDefense Health Agency
  7. Universal Plasma Generator for Selective Removal of Anti-A and Anti-B Antibodies from Donor Plasma

    SBC: LYNNTECH INC.            Topic: DHP15B001

    Traumatic injury accounts for 14.2% of all fatalities. Clinical management of trauma often requires massive plasma transfusions. However, in critical combat casualty care or in civilian emergency trauma care, plasma of compatible blood group may not be readily available. Transfusion with incompatible plasma may result in potentially fatal hemagglutination in the recipient. Typeless or universal pl ...

    STTR Phase II 2017 Department of DefenseDefense Health Agency
  8. Cervical Spine Health Improvement Products

    SBC: SWITCHBOX INC            Topic: DHA18B001

    Most standard-of-care tools and techniques for evaluating neck disorders are subjective, unreliable, and do not provide actionable information for providers, payers, and organizations to deliver efficient and effective care. This lack of objective neck he

    STTR Phase I 2019 Department of DefenseDefense Health Agency
  9. Novel Circulating RNA-based Markers as Diagnostic Biomarkers of Infectious Diseases

    SBC: CFD RESEARCH CORPORATION            Topic: CBD18A001

    In resource limited settings, rapid and accurate diagnosis of infections is critical for managing potential exposures to highly virulent pathogens,whether occurring from an act of bioterrorism or a natural event. This is especially important for hard to detect intracellular bacterial andalphavirus infections, that overlap symptomatically and often treated empirically due to a lack of reliable and ...

    STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense
  10. Virus-Like Particle Based pan-Marburgvirus Vaccine

    SBC: LUNA INNOVATIONS INCORPORATED            Topic: CBD18A002

    Marburg virus (MARV) is a filamentous enveloped non-segmented negative sense RNA virus. This viruse is considered to be extremelydangerous with case fatality rates as high as 88-90%. Extensive efforts have gone towards effective vaccines for MARV prevention, however,none have been successfully established as licensed vaccines. Glycoprotein (GP) is the only surface protein of MARV. There are substa ...

    STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense
US Flag An Official Website of the United States Government